Unigestion Holding SA Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Unigestion Holding SA increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 20.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,643 shares of the medical research company’s stock after buying an additional 444 shares during the quarter. Unigestion Holding SA’s holdings in IQVIA were worth $519,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at about $33,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. increased its stake in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on IQV. Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Truist Financial restated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Down 7.8 %

Shares of IQVIA stock opened at $154.63 on Monday. IQVIA Holdings Inc. has a twelve month low of $153.42 and a twelve month high of $252.88. The firm’s 50-day moving average price is $189.67 and its 200 day moving average price is $203.55. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $27.26 billion, a PE ratio of 20.62, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.